Pain Therapeutics Changes Phase III Protocol For Abuse-Resistant Opioids
This article was originally published in The Pink Sheet Daily
Company expects to file NDA for abuse-resistant oxycodone in late 2007.
You may also be interested in...
Payment includes possible royalties from alternate formulations of the extended-release morphine product developed through a King/Elan partnership.
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.